Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

Ivette Maldonadoa, Manuel Platab, Mauricio Gonzézc, Alfonso Correaa, Claudia Nossaa, Anna R. Giulianoa, Elmar A. Joura, Alex Ferenczyh, Brigitte M. Ronnetta, Mark H. Stolerj, Hao Jin Zhou,** Amita Joshib, Rituparna Dasb, Oliver Bautista, Thomas Group, Alain Luxembourg, Alfred Sahah, and Ulrike Kirsten Buchwaldh

Department of Obstetrics & Gynaecology, Fundación Santa Fe de Bogotá, Bogotá; Colombia; dDepartment of Gynaecology, Fundación Cardioinfantil, Bogotá, Colombia; eGinecologo Oncologo, Instituto Nacional de Cancerología, Bogotá, Colombia; fClinica del Country, Bogotá, Colombia; gCafam, Bogotá, Colombia; hCenter for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA; iDepartment of Obstetrics & Gynaecology, Medical University of Vienna, Vienna, Austria; jDepartment of Gynecologic Pathology and Cytopathology, University Health Center and Jewish General Hospital, Montreal, Quebec, Canada; kJohns Hopkins Gynecologic Pathology Consultation Service, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; lDepartment of Pathology, University of Virginia Health System, Charlottesville, VA, USA; mMerck & Co., Inc, Rahway, NJ, USA

ABSTRACT
Among women aged 27–45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was also generally well tolerated and highly immunogenic in men aged 27–45 years who participated in the single-cohort mid-adult male (MAM) study (NCT01432574; n = 150). Here, we report results of a long-term follow up (LTFU) extension of FUTURE III with up to 10 years follow-up. To understand the relevance of the mid-adult women LTFU study in the context of mid-adult men vaccination, we report results from post-hoc, cross-study immunogenicity analyses conducted to compare immunogenicity (geometric mean titers; GMTs) at 1-month post-qHPV vaccine dose 3 in women and men aged 27–45 years versus men and women aged 16–26 years from prior efficacy studies. The qHPV vaccine demonstrated durable protection against the combined endpoint of HPV6/11/16/18-related high-grade cervical dysplasia and genital warts up to 10 years (median 8.9) post-dose 3 and sustained HPV6/11/16/18 antibody responses through approximately 10 years in women aged 27–45 years. Efficacy of qHPV vaccine in men aged 27–45 years was inferred based on the cross-study analysis of qHPV vaccine immunogenicity demonstrating non-inferior HPV6/11/16/18 antibody responses in men aged 27–45 years versus 16–26 years. In conclusion, durable effectiveness of the qHPV vaccine was demonstrated in women 27–45 years of age, and vaccine efficacy was inferred in men 27–45 years of age based on the serological results.

Introduction
The burden of human papillomavirus (HPV)-related disease remains substantial in adult women, with approximately 125,000 cases of high-grade cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS) diagnosed in US women aged 30 years or older in 2016 (of 196,000 US cases diagnosed overall). Also, men do not appear to develop effective immunity following natural HPV infection and experience recurrent HPV infection and related disease throughout their lifetime as shown in several analyses from the HPV Infection in Men (HIM) study, a prospective natural history study of HPV infection in men. Overall, adults remain at risk of acquisition of HPV infection and vaccination of this population remains a significant unmet medical need.

The quadrivalent (qHPV) vaccine demonstrated efficacy and immunogenicity in women aged 24–45 years in the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) III study. To further the understanding of the applicability of these findings, we report long-term effectiveness and immunogenicity of the qHPV vaccine in adult women from FUTURE III after 10 years of follow-up. To understand the relevance of the mid-adult women LTFU study in the context of mid-adult men vaccination, we also report evidence of effectiveness against HPV-related disease in mid-adult men based on immunogenicity bridging analyses of historic data in younger (aged 16–26 years) clinical efficacy trial participants to mid-adult clinical trial participants (aged 27–45 years).

Methods
Study design and population
Two clinical studies were conducted in adults aged 27–45 years: one in adult women, the (FUTURE III study (Protocol V501–019; NCT00090220); and one among adult men, the Mid-Adult Males (MAM) study (Protocol V501–108; NCT01432574).
The FUTURE III study, a phase III, randomized, placebo-controlled, multinational, multicenter, double-blind, safety, immunogenicity, and efficacy study, enrolled 3819 women aged 24–45 years in seven countries (Colombia, France, Germany, Spain, the Philippines, Thailand, and the United States). Participants were equally randomized to receive three doses of qHPV vaccine or placebo (at Day 1, Month 2, and Month 6) and followed over approximately 4 years. The design and the results of the base study have been reported. 6,7 Participants who had received placebo or an incomplete regimen of the qHPV vaccine were then offered vaccination with the qHPV vaccine. Participants from Colombia who received ≥1 dose of qHPV vaccine or placebo were eligible for enrollment in a 6-year, open-label LTFU extension. The study sites from Colombia were selected for LTFU because of the relatively large proportion of participants enrolled in this country in the base study (N = 1610; 42%) and willingness of the five investigators from Colombia to continue to follow the participants. Two cohorts were assessed: the early vaccination group (EVG), whose participants received qHPV vaccine during the base study, and the catch-up vaccination group (CVG), whose participants received placebo during the base study and qHPV vaccine once efficacy was demonstrated. EVG participants were followed for approximately 10 years after their first qHPV vaccine dose (i.e., approximately 4 years in the base study plus 6 years in LTFU). CVG participants received their first dose of qHPV vaccine more than 4 years after their base study enrollment. They were therefore older at vaccination (i.e., those aged 27–45 years at enrollment were vaccinated at age 32–50 years) and followed for approximately 4.5 years post-qHPV vaccine dose 1. No qHPV vaccination occurred during LTFU (Figures 1 and S1).

In many countries, HPV vaccines are widely used in individuals aged 9–26 years. 9,10 Therefore, in this analysis, we focus on the subset of participants aged 27–45 years at enrollment in FUTURE III to help inform public health decisions and vaccination recommendations.

The MAM study was a phase II, open-label, single-arm, immunogenicity, and safety study in men aged 27–45 years who received three doses of the qHPV vaccine. The study enrolled 150 men from two countries (Mexico and the United States) between February and October 2013 from a cohort of men who had completed a 4-year follow-up in the HIM study. The study design and the results have been reported. 8

The study protocols were approved by institutional review boards at each participating center. All participants provided informed consent prior to the FUTURE III base study and again before the LTFU as well as prior to the MAM study. Each study was conducted in conformance with applicable country or local requirements regarding ethical committee review, informed consent, and other statutes or regulations regarding the protection of the rights and welfare of human subjects participating in biomedical research.

Follow-up

During the FUTURE III LTFU, gynecological examinations were conducted to detect external genital lesions (EGLs) and cervical cytology samples were collected at Months 72, 96, and 120 using the same methodology as in the base study. 6,7 New EGLs assessed to be possibly, probably, or definitely HPV-related, or of unknown etiology, were biopsied. Participants with cytological abnormalities were referred for

![Figure 1](#)

Figure 1. Study design of FUTURE III LTFU. Catch-up vaccination was approximately 5 years after base study Day 1. Participant numbers (n) for the base study and LTFU period refer to participants vaccinated and entering LTFU, respectively (women aged 24–45 years). Abbreviations: HPV, human papillomavirus; LTFU, long-term follow-up; Mo, Month; qHPV, quadrivalent HPV.
colposcopy based on a protocol-specified triage algorithm. Tissue samples were adjudicated by a pathology panel and tested for HPV DNA by PCR as previously described. Serum HPV antibodies were assessed at Months 72, 96, and 120 using competitive Luminex immunoassay (cLIA), and at Month 120 using immunoglobulin G Luminex immunoassay (IgG LIA). Deaths, serious AEs (SAEs) considered vaccine- or procedure-related, and pregnancy outcomes were collected during LTFU. A diagram of the entire study is shown in Figure 1.

In the MAM study, all participants received three doses of the qHPV vaccine (at Day 1 and Months 2 and 6). Serum HPV antibodies were assessed at Day 1 and Month 7 using cLIA.8

Statistical analysis

Efficacy/effectiveness

Vaccine efficacy was not assessed in the LTFU study because no placebo comparison group was available. Instead, vaccine effectiveness was assessed based on the incidence rate of the endpoint HPV6/11/16/18-related CIN and condyloma and interpreted in the context of the incidence rate of the same endpoint in the vaccine and placebo groups of the base study. The per-protocol efficacy (PPE) population consisted of EVG participants who were seronegative at Day 1 and PCR-negative from Day 1 to Month 7 for the HPV type being analyzed, received all three doses of the correct clinical material within one year, had no protocol violations that could affect the evaluation of vaccine efficacy, and attended at least one LTFU visit. Cases were counted starting at Month 7. PPE analyses were not conducted for CVG participants because their last PCR and serology testing was at their last base study visit and the qHPV vaccine was given only after a lag (between the end of the base study and the start of LTFU) when they might have become PCR- and/or serology-positive to a new HPV type. Undetected HPV infection occurring between the last base study visit and the first dose of qHPV vaccine could potentially reduce the measured vaccine effectiveness in this population. An intention-to-prevent (ITP) population included participants who were seronegative and PCR-negative to the relevant HPV type prior to qHPV vaccination (at Day 1 for EVG participants; from Day 1 of the base study to the last follow-up visit prior to vaccination with qHPV vaccine for CVG participants), received ≥1 dose of qHPV vaccine or placebo, and had at least one LTFU visit. Cases for the ITP analyses were counted starting at Day 1. A modified intention-to-prevent (mITP) population for analysis of incidence of cervical disease and genital warts caused by non-vaccine HPV types was defined similarly, except that prior to qHPV vaccination participants were seronegative to four HPV types (HPV6/11/16/18), PCR-negative to fourteen HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59), and had normal cervical cytology (defined as negative for squamous intraepithelial lesions). Counting of follow-up time for effectiveness of qHPV vaccination was done starting at post-dose 1 (relevant to the ITP analyses) and starting at post-dose 3 (relevant to the PPE analyses) through the last LTFU visit with assessment for cervical or external genital disease or cytological abnormalities.

Incidence of effectiveness endpoints per 10,000 person-years of follow-up and 95% exact Poisson confidence intervals (CIs) were reported based on: (1) total follow-up time within the LTFU period, and (2) total follow-up time during the base study period. When feasible, the percent reduction in the incidence rates in the EVG relative to those in the CVG were assessed and calculated as 100 × (1 – relative risk), where relative risk is the ratio of the incidence in the EVG relative to the CVG.

Immunogenicity

Immunogenicity was analyzed in the per-protocol immunogenicity (PPI) population. In FUTURE III, the PPI population included participants in the PPE population who received doses 2 and 3 within pre-specified day ranges and had an evaluable serology result within 14–49 days after dose 3. In the MAM study, PPI participants received all three qHPV vaccine doses and were seronegative and genital HPV-negative to the relevant HPV type prior to vaccination.8 Geometric mean titers (GMTs) at 1 month post-dose 3 of qHPV vaccine were compared in participants aged 27–45 years versus participants aged 16–26 years. Women aged 27–45 years (Group A) were from FUTURE III; women aged 16–26 years (Group B) were from FUTURE I,11 FUTURE II,17 and FUTURE III (i.e., women aged 24–26 years at enrollment); men aged 27–45 years (Group C) and 16–26 years (Group D) were from the MAM study and Protocol V501–020, respectively. The ratios of GMTs (women aged 27–45 years/women aged 16–26 years [Group A/Group B], and men aged 27–45 years/men aged 16–26 years [Group C/Group D]) and corresponding two-sided 95% CI were calculated. All comparisons were post-hoc. There was no pre-specified non-inferiority hypothesis testing.

Safety

Deaths and vaccine- and procedure-related SAEs were collected for the entire duration of the LTFU study. Safety results in the MAM study have been reported.8

Results

Long term follow-up of adult women for effectiveness, immunogenicity, and safety in the FUTURE III study

The base study was conducted from 18 June 2004, to 30 April 2009, with LTFU conducted from 14 January 2011, to 12 November 2015. A total of 3253 base-study participants were aged 27–45 years (Figure S1). These included 1408 participants from Colombia, of whom 1189 (EVG = 600; CVG = 589) participated in LTFU. CVG participants received their qHPV vaccination doses 1 approximately 5 years (60 months) after the start of the base study (reflected in a difference of 5 years in median age at Day 1 in base study and at timepoint prior to catch-up vaccination, Table 1). Table 1 shows the baseline characteristics of EVG and CVG participants who continued into LTFU; Table S1 shows baseline characteristics of base study participants who did not continue into the LTFU extension. Baseline characteristics were generally similar among EVG and CVG participants.
The median follow-up time for effectiveness in the LTFU study in EVG participants aged 27–45 years was 9.6 years (range: 5.9–10.6 years) post-dose 1 or 9.1 years (range: 5.5–10.1 years) post-dose 3. The median follow-up time for effectiveness in the LTFU study in CVG participants was 4.5 years (range: 0.7–5.3 years) post-dose 1 or 4.0 years (range: 0.3–4.9 years) post-dose 3.

Among EVG participants in the PPE population, the incidence rates of HPV6/11/16/18-related CIN and condyloma, HPV16/18-related CIN2 or worse, and HPV6/11-related condyloma were similar during the LTFU period compared with the base study period (Table 2). Overall, there were no cases of HPV6/11/16/18-related CIN and condyloma during both the base study and LTFU period. Among EVG participants in the ITP population, the incidence rates of HPV6/11/16/18-related CIN and condyloma, HPV16/18-related CIN2 or worse, and HPV6/11-related condyloma were similar or lower during the LTFU period compared with the base study period (Table 2).

Among CVG participants in the ITP population, the incidence rates of HPV6/11/16/18-related CIN and condyloma, HPV16/18-related CIN2 or worse, and HPV6/11-related condyloma were lower during the LTFU period (i.e., after qHPV vaccination) compared with rates during the base study period (i.e., placebo arm of the base study) (Table 2).

During the base study, the incidence rates of HPV6/11/16/18-related CIN and condyloma in the PPE and ITP populations were lower in the EVG compared with respective rates in the CVG (Table 2). The percent risk reduction (100% and 94.3%, respectively, in PPE and ITP analyses) was equivalent to and consistent with the statistically significant vaccine efficacy observed with qHPV vaccine in the full base study population.\(^\text{6,7}\) After CVG participants were administered the qHPV vaccine regimen, the incidence rate of HPV6/11/16/18-related CIN and condyloma in the ITP population of the CVG during LTFU was similar to the rate in the EVG during the base study and LTFU period (Table 2). This result indicates that the qHPV vaccine provided protection against HPV-related disease after qHPV vaccination in the CVG.

Among EVG participants, the incidence of HPV6/11/16/18-related disease endpoints during the base study was higher among those who did not continue in the LTFU study extension versus those who participated (Table S2). Vaccine efficacy against HPV6/11/16/18-related disease endpoints was similar or comparable in LTFU participants and non-participants (Table S2).

Incident cases of CIN and condyloma related to non-vaccine types (including HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) were observed during the base and LTFU study among EVG and CVG participants in the mITP population, indicating ongoing exposure to HPV and risk of acquiring new infections during both the base and LTFU study (Table 3).

Regarding immunogenicity in EVG participants, GMTs for all vaccine HPV types peaked at Month 7, declined sharply up to Month 24 and more gradually thereafter, and persisted throughout the study (Figure 2; Table S3). At Month 120, seropositivity rates for HPV6/11/16/18, respectively, were 78%, 85%, 94%, and 35% when assessed by cLIA, and 87%, 79%, 100%, and 84% when assessed by IgG LIA (Table S4). In the CVG participants, serum collections following catch-up vaccination at study Months 72, 96, and 120 (Figure 1) correspond to approximately 12, 36, and 60 months post-qHPV vaccination dose 1 in this group. GMTs and seropositivity rates at Months 72 and 96 in the CVG were comparable to those at Months 12 and 36 post-dose 1 in the EVG participants (Tables S3 and S4). Analyses of immunogenicity in the EVG by age strata (27–34 years and 35–

---

Table 1. Baseline characteristics of LTFU participants aged 27–45 years in the FUTURE III study.\(^\text{a}\)

|                        | EVG (N = 600) | CVG (N = 589) |
|------------------------|--------------|--------------|
| **Age (y)**            |              |              |
| Mean (SD)              | 37 (5.4)     | 36 (5.3)     |
| Median (range)         | 37 (27–45)   | 36 (27–45)   |
| 27–34 years old, n (%) | 218 (36.3)   | 233 (39.6)   |
| 35–45 years old, n (%) | 382 (63.7)   | 356 (60.4)   |
| >45 years old, n (%)   | 0 (0.0)      | 0 (0.0)      |
| **Lifetime number of sex partners** |              |              |
| Mean (SD)              | 3 (2.4)      | 3 (2.8)      |
| Median (range)         | 2 (1–26)     | 2 (1–42)     |
| No response, n (%)     | 1 (0.2)      | 1 (0.2)      |
| **HPV status by serology and PCR** |              |              |
| Seropositive, n/total evaluable (%) |              |              |
| EVG 6/11/16/18         | 166/600 (27.7) | 187/589 (31.7) | 191/589 (32.4) |
| HPV 11                 | 82/600 (13.7) | 88/589 (14.9) | 100/589 (17.0) |
| HPV 16                 | 30/600 (5.0)  | 30/589 (5.1)  | 32/589 (5.4)   |
| HPV 18                 | 81/600 (13.5) | 93/589 (15.8) | 97/589 (16.5)  |
| PCR-positive, n/total evaluable (%) |              |              |
| EVG 6/11/16/18         | 45/596 (7.6)  | 39/581 (6.7)  | 49/589 (8.3)   |
| HPV 16                 | 6/595 (1.0)   | 12/580 (2.1)  | 16/589 (2.7)   |
| HPV 11                 | 1/595 (0.2)   | 1/581 (0.2)   | 2/589 (0.3)    |
| HPV 18                 | 23/595 (3.9)  | 22/580 (3.8)  | 23/589 (3.9)   |
| PCR-positive, n/total evaluable (%) |              |              |
| EVG 6/11/16/18         | 15/596 (2.5)  | 10/581 (1.7)  | 12/589 (2.0)   |

\(^\text{a}\)Age at base study Day 1.

\(^\text{b}\)Prior to qHPV catch-up vaccination encompasses approximately 5 years after base study Day 1.

Abbreviations: CVG, catch-up vaccination group; EVG, early vaccination group; HPV, human papillomavirus; LTFU, long-term follow-up qHPV, quadrivalent human papillomavirus; SD, standard deviation.
Table 2. Reduction in incidence of HPV-related cervical disease and genital warts in women 27–45 years of age who participated in the FUTURE III LTFU study.

|                   | EVG (N = 600) Person-Years Follow-up | Incidence per 10,000 Person-Years Cases (95% CI) | CVG (N = 589) Person-Years Follow-up | Incidence per 10,000 Person-Years Cases (95% CI) | Risk Reduction* (%) Estimate (95% CI) |
|-------------------|-------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|--------------------------------------|
| **HPV6/11/16/18-related CIN or condyloma** |                                     |                                               |                                     |                                               |                                      |
| Per-protocol populationa | Base study 0/528 1794.2 0.0 (0.0–20.6) | 13/528 1785.6 72.8 (38.8–124.5) 100 (71.1, 100) | LTFU study 0/529 2946.7 0.0 (0.0–12.5) | — | — |
|                     | ITP populationb | Base study 1/587 2308.8 4.3 (0.1–24.1) 75.8 (44.1–121.3) 94.3 (65.8, 99.7) | LTFU study 0/586 3263.0 0.0 (0.0–11.3) | — | — |
| **HPV16/18-related CIN 2 or worse** | Per-protocol populationa | Base study 0/513 1694.2 0.0 (0.0–21.8) 17.7 (3.7–51.8) 100 (71.3, 100) | LTFU study 0/482 2679.0 0.0 (0.0–13.8) | — | — |
|                     | ITP populationb | Base study 1/578 2192.8 4.6 (0.1–25.4) 18.7 (5.1–48.0) 75.7 (86.8, 99.0) | LTFU study 0/535 2976.8 0.0 (0.0–12.4) | — | — |
| **HPV6/11-related condyloma** | Per-protocol populationa | Base study 0/443 1505.7 0.0 (0.0–24.5) 13.7 (1.7–49.6) 100 (235.8, 100) | LTFU study 0/443 2460.4 0.0 (0.0–15.0) | — | — |
|                     | ITP populationb | Base study 0/491 1937.3 0.0 (0.0–19.0) 21.7 (5.9–55.6) 100 (6.0, 100) | LTFU study 0/491 2724.6 0.0 (0.0–13.5) | — | — |

*Risk reduction refers to percent reduction in incidence in the EVG versus CVG during the indicated period, calculated as 100 × (1 – incidence in EVG/incidence in CVG). During the LTFU study, the comparison of EVG and CVG represents comparison of incidence in similarly qHPV vaccinated groups.

aThe per-protocol effectiveness population included EVG participants who received all three vaccine doses, were seronegative at Day 1 and PCR-negative from Day 1 through Month 7 of the base study for the HPV type being analyzed, had no protocol violations that could affect vaccine efficacy evaluation, and attended at least one visit during LTFU. Per-protocol analyses were not conducted for CVG participants because their last PCR and serology testing was at their last base study visit and the qHPV vaccine was given only after a lag.

bThe ITP population for the EVG and CVG included participants who received at least one vaccine dose, were seronegative and PCR-negative for the type analyzed prior to qHPV vaccination (at Day 1 of the base study for EVG participants; from Day 1 of the base study to the last follow up visit prior to vaccination with qHPV vaccine for CVG participants), and had at least one LTFU visit.

cAbbreviations: CI, confidence interval; EVG, catch-up vaccination group; EVG, early vaccination group; ITP, intention-to-prevent (HPV-naïve to the relevant type); LTFU, long-term follow-up; m, number of endpoint cases; N, number of participants in the LTFU study; n, number of participants in the analysis population with follow-up in the indicated study period.

**Comparison of qHPV vaccine immunogenicity in women and men aged 27–45 years versus women and men aged 16–26 years**

In the post-hoc, cross-study immunogenicity analyses in the PPI population, the point estimates of the GMT ratios for adult women/young women (Group A/Group B) ranged from 0.71 to 0.96, and for adult men/young men (Group C/Group D) from 0.74 to 0.91 (Table 4). The lower bound of the 95% CI of the GMT ratios was >0.5 for all comparisons.

**Discussion**

Effectiveness analyses in the EVG showed no breakthrough cases of CIN or genital warts related to HPV6/11/16/18 for up to 10 years following qHPV vaccination of women aged 27–45 years. Among CVG participants, the incidence of HPV6/11/16/18-related CIN and EGL was lower post-vaccination (LTFU period) compared with the pre-vaccination incidence during the base study period, with no cases observed during LTFU. Although vaccination in the CVG was delayed 4 years such that participants were 32–50 years of age at the time of qHPV vaccination, it still provided effective protection against additional vaccine HPV type-related disease to which participants remained susceptible. Persistence of HPV6/11/16/18 antibody responses was observed through 10 years following vaccination. There were no vaccine-related SAEs during the LTFU study period.

In post-hoc, cross-study analyses, the point estimates of anti-HPV6/11/16/18 GMTs at Month 7 were lower in individuals aged 27–45 years compared with individuals aged 16–26 years; however, a greater than two-fold decrease in GMTs was ruled out. This criterion was used in previous studies of the qHPV vaccine program to demonstrate non-inferiority of HPV antibody responses and infer vaccine efficacy based on immunogenicity assessment and is an accepted regulatory pathway.19,20

Prophylactic HPV vaccination is ideally administered to young adolescents prior to exposure to HPV. However, optimal vaccine coverage has not yet been reached in adolescents in many countries.21 Moreover, catch-up vaccination of...
Table 3. Incidence of nonvaccine HPV type-related cervical disease and genital warts in women 27–45 years of age who participated in the LTFU study (mITP population

| HPV 3/13/35/39/45/51/52/56/58/59-related CIN or condyloma | EVG (N = 600) | CVG (N = 589) | Risk Reduction (%) |
|-------------------------------------------------------------|---------------|---------------|-------------------|
| Incidence per Person-Years | Person-Years Follow-up | Incidence per Person-Years | Person-Years Follow-up | Incidence per Person-Years | Person-Years Follow-up | Risk Estimate (%) |
| HPV 3/13/35/39/45/51/52/56/58/59-related CIN or condyloma | | | | | | |
| Base study | | | | | | |
| LTFU study | 7/298 | 1170.4 | 59.8 (24.0–123.2) | 8/287 | 1118.2 | 71.5 (30.9–141.0) | 16.4 (−129.5, 74.2) |
| HPV 3/13/35/39/45/51/52/56/58/59-related CIN or condyloma | | | | | | |
| Base study | | | | | | |
| LTFU study | 2/291 | 1616.2 | 12.4 (1.5–44.7) | 3/280 | 1245.3 | 24.1 (5.0–70.4) | 48.6 (−230.1, 93.6) |

*The mITP population for the EVG and CVG included participants who received at least one vaccine dose, had at least one LTFU visit, and at Day 1 of the base study were: seronegative to four HPV types (6, 11, 16, 18), PCR negative to fourteen HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), and had normal cervical cytology (defined as negative finding for squamous intraepithelial lesions).

*Risk reduction refers to percent reduction in incidence in the EVG versus CVG during the indicated period, calculated as 100 × (1 − incidence in EVG/incidence in CVG). During the LTFU study, the comparison of EVG and CVG represents comparison of incidence in similarly qHPV vaccinated groups.

Abbreviations: CI, confidence interval; CVG, catch-up vaccination group; EVG, early vaccination group; LTFU, long-term follow-up; m, number of endpoint cases; mITP, modified intention-to-prevent (generally HPV-naive); N, number of participants in the LTFU study; n, number of participants in the analysis population with follow-up in the indicated study period.
unvaccinated adults has not been consistently implemented. As a result, most adult men and women are not protected against the HPV types targeted by HPV vaccines.

Adults remain susceptible to acquiring new HPV-vaccine-preventable infections. As previously reported, at the baseline FUTURE III trial visit, most prevalent infections contained only one HPV type, and approximately 84% of participants were HPV DNA-negative to all nine HPV types covered by the 9vHPV vaccine, and thus would gain protection from vaccination. Additionally, qHPV vaccine prevents re-infection in women with serological evidence of previous HPV infection and who are PCR-negative and provides protection from subsequent disease after surgical treatment for HPV-related disease.

Adult women in the control arms of the HPV vaccine trials continued to acquire new HPV infections over time. In the placebo arm of FUTURE III, incident 6-month HPV6/11/16/18-related persistent infection was observed in 5% of the PPE population over a 4-year follow-up. In the HIM study, adult men were observed to remain at risk for acquiring new HPV infection throughout their lifespans. HPV infections in adult women progress to high-grade CIN at rates similar to young women. In the placebo groups of qHPV vaccine efficacy studies in women, the rate of progression of HPV16/18-related persistent infection to HPV16/18-related CIN2 or worse in women aged 27–45 years (2.9/100 person-years; 95% CI: 1.9; 4.3) was similar to that in women aged 16–26 years (2.6/100 person-years; 95% CI: 2.0; 3.3). Similarly, in the placebo

---

**Table 4.** Comparison of anti-HPV GMTs at Month 7 (1 month post-dose 3) in women aged 27–45 years (FUTURE III study) versus women aged 16–26 years (FUTURE I, FUTURE II, and FUTURE III studies) and men aged 27–45 years (MAM study) versus men aged 16–26 years (V501–020 study) who received three doses of the qHPV vaccine (PPI population).

| Assay (cLIA) | Women aged 27–45 years (Group A) | Women aged 16–26 years (Group B) | Group A/Group B |
|--------------|---------------------------------|---------------------------------|----------------|
| Anti-HPV 6   | n 1083 GMT (mMU/mL) 412.4        | n 2800 GMT (mMU/mL) 536.2       | GMT ratio 0.77 |
| Anti-HPV 11  | n 1083 GMT (mMU/mL) 538.2        | n 2824 GMT (mMU/mL) 754.3       | CI 0.72; 0.82  |
| Anti-HPV 16  | n 1092 GMT (mMU/mL) 2212.0       | n 2749 GMT (mMU/mL) 2297.6      |               |
| Anti-HPV 18  | n 1223 GMT (mMU/mL) 348.4        | n 3006 GMT (mMU/mL) 458.1       |               |

| Assay (cLIA) | Men aged 27–45 years (Group C) | Men aged 16–26 years (Group D) | Group C/Group D |
|--------------|--------------------------------|--------------------------------|----------------|
| Anti-HPV 6   | n 115 GMT (mMU/mL) 364.9        | n 1092 GMT (mMU/mL) 447.6       | GMT ratio 0.82 |
| Anti-HPV 11  | n 136 GMT (mMU/mL) 489.9        | n 1092 GMT (mMU/mL) 624.0       | CI 0.65; 1.03  |
| Anti-HPV 16  | n 111 GMT (mMU/mL) 2177.8       | n 1135 GMT (mMU/mL) 2404.3      |               |
| Anti-HPV 18  | n 135 GMT (mMU/mL) 296.2        | n 1174 GMT (mMU/mL) 402.3       |               |

Abbreviations: CI, confidence interval; cLIA, competitive Luminex immunoassay; GMT, geometric mean titer; HPV, human papillomavirus; mMU/mL, milli Merck units per milliliter; qHPV, quadrivalent human papillomavirus.
arm of the bivalent HPV vaccine efficacy study in women ≥25 years (90% of whom were aged 25–45 years), persistent HPV infections lasting ≥6 months progressed within 48 months to low-grade and high-grade cervical lesions at rates similar to young women.30

A major strength of FUTURE III is to establish long-term effectiveness, using the same rigorous methodology in the base study and LTFU study. A similar methodology was also used in other LTFU studies of the qHPV vaccine in girls aged 9–15 years31 and women aged 16–23 years.32 Collectively, these studies established long-term effectiveness (≥10 years) in females aged 9–45 years. This LTFU study lacked a control group, since participants in the placebo arm were offered qHPV vaccination after the base study. Nonetheless, the absence of breakthrough cases and the continued exposure to non-vaccine HPV types during the LTFU study provide robust evidence of sustained vaccine effectiveness. The absence of breakthrough cases cannot be explained by herd protection since the national HPV vaccination program in Colombia was only initiated in 2012 and primarily targeted girls aged 9–18 years. No effectiveness assessment was conducted in men. However, efficacy results previously established in men aged 16–26 years can be extended to men aged 27–45 years based on the demonstration of non-inferior immunogenicity.

Overall, durable effectiveness of the qHPV vaccine was demonstrated in women aged 27–45 years and inferred in men aged 27–45 years. These results support catch-up vaccination programs of sexually active adults who have not been previously vaccinated as adolescents or young adults. Vaccination of adults may be important in obtaining rapid reductions in the incidence of all HPV-related cancers and diseases worldwide.33

Acknowledgments

The authors would like to thank the study participants and investigators, and Robert Kurman for contributions serving on the pathology panel. Rodney Finalle, Barbara Kuter, Vimalanand Prabhu, Miriam Reuschenbach, Kunal Saxena, and Christine Velicer, all of Merck & Co., Inc., Rahway, New Jersey, USA, reviewed and provided feedback on a draft of this manuscript.

Disclosure statement

IM: Ivette Maldonado has received grants through her institutions for board membership and study conduct.

MP: Manuel Plata has received grants through his institutions for study conduct and support for travel. He has also received honoraria from the Fundación Cardioinfantil.

MG: Mauricio Gonzalez has grants via his institution to serve as an investigator and colposcopist of FUTURE III study (Protocol 019).

AC: Alfonso Correa has no interests to declare.

CN: Claudia Nossa has no interests to declare.

AG: Anna R. Giuliano reports grant support from, and is an advisory board member for, Merck & Co., Inc.

EJ: Elmar Joura reports grants from Merck during the conduct of the study and personal fees from Merck Sharp & Dohme (MSD) outside the submitted work.

AF: Alex Ferenczy received consultation fees from MSD as a member of the Pathology Panel.

BR: Brigitte M. Ronnett is a consultant for MSD as part of the Pathology Panel.

MS: Mark H. Stoler has received personal fees from MSD, Roche, Becton Dickinson, and Invivo Pharmaceuticals as a consultant, all outside of the submitted work.

HJJ: Hao Jin Zhou is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

AJ: Amita Joshi is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

RD: Rita Das is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

OB: Oliver Bautista is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

TG: Thomas Group is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

AL: Alain Luxembourg is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

AS: Alfred Saah is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

UB: Ulrike Buchwald is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

Funding

Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Editorial support, under the direction of the authors, was provided by Erin Bekes, PhD, of CMC AFFINITY, a division of McCann Health Medical Communications Inc., Hackensack, New Jersey, USA, funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA, in accordance with Good Publication Practice (GPP3) guidelines.

ORCID

Anna R. Giuliano http://orcid.org/0000-0002-5440-8859
Elmar A. Joura http://orcid.org/0000-0003-0885-1013
Ulrike Kirsten Buchwald http://orcid.org/0000-0002-6671-0115

References

1. McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Schall M, Nicolai LM, Brackney M, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women — United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68:337–43. doi:10.15585/mmwr.mm6815a1.

2. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377:932–40. doi:10.1016/S0140-6736(10)62342-2.

3. Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, Lazcano-Ponce E, da Silva RJC, Baggio ML, Quiterio M, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res. 2012;72:676–85. doi:10.1158/0008-5472.CAN-11-0751.

4. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, Cintra RC, Lazcano-Ponce E, Villa LL. Genital wart recurrence among men residing in Brazil, Mexico, and the United States. J Infect Dis. 2019;219(5):703–10. doi:10.1093/infdis/jiy533.
11. Vardas J, Clinical Immunol. 2012 nine type-specific Smith and Bryan Harper Markowitz countries Gemayel Bonanni Ingles Giuliano Viscidi 2010 validation Cancer. K, recommendation, A, and JF, 2010 vaccinating for HPV infection and anogenital Lachman Kreimer virus and virus-like Pitisuttithum vaccine and vaccination and recombinant vaccine among women aged older than 24–45 years to have immunity in study. BMJ. 2012;344(march 27 3):e1401. doi:10.1136/bmj.e1401.

12. Dias D, Van Doren J, Schlotmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12:959–69. doi:10.1128/CDLI12.8.959-969.2005.

13. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10:108–15.

14. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryant JT. Evolution of type-specific immunoadsays to evaluate the functional immune response to Gardasil: a vaccine for human papillomaviruses types 16, 18, 6 and 11. Hum Vaccin. 2008;4:134–42. doi:10.4161/hv.4.2.15261.

15. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol. 2010;17:818–27. doi:10.1128/CVI.00348-09.

16. Saah A, Bautista O, Luxembourg A, Perez G. Intention-To-Prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies. Contemp Clin Trials Commun. 2017;7:189–93. doi:10.1016/j.conctc.2017.07.010.

17. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. doi:10.1056/NEJMoa061741.

18. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, et al. Immunogenicity of the quadrivalent human papillomavirus vaccine (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012;19:261–67. doi:10.1128/CVI05208-11.
30. Skinner SR, Wheeler CM, Romanowski B, Castellsague X, Lazcano-Ponce E, Del Rosario-Raymundo MR, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138:2428–38.

31. Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, et al. 4-Valent human papillomavirus (4vhpv) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140:ii:e20163947.

32. Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020;23:100401.

33. Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13:119–32.